Basal cell subpopulation as putative human prostate carcinoma stem cells

Folia Histochemica et Cytobiologica

Volumn 45, Issue 2, 2007, Pages 75-80

  Kuzmanov, Aleksandar ^a   Hayrabedyan, Soren ^a   Karaivanov, Milen ^b   Todorova, Krassimira ^a  

^a BULGARIAN ACADEMY OF SCIENCES   (Bulgaria)

^b University Hospital   (Bulgaria)

Author keywords

AMACR; GSTP1; p63; PHPCSC; Quantitative immunohistochemistry

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BIOTIN; GLUTATHIONE TRANSFERASE P1; PEROXIDASE; PROTEIN ANTIBODY; PROTEIN P63; STREPTAVIDIN;

ADULT; AGED; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BASAL CELL; CARCINOMA CELL; CELL ASSAY; CELL PROLIFERATION; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRECANCER; PROSTATE CARCINOMA; PROSTATECTOMY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STEM CELL;

EID: 34250672821     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Res, 2006; 66: 7589-7597
2. Bui M, Reiter RE. Stem cell genes in androgen-independent prostate cancer. Cancer Metastasis Rev, 1998; 17: 391-399
3. De Marzo AM, Meeker AK, Epstein JI, Coffey DS. Prostate stem cell compartments: expression of the cell cycle inhibitor p27Kip1 in normal, hyperplastic, and neoplastic cells. Am J Pathol, 1998; 153: 911-919
4. Hayrabedyan S, Kehayov I, Kyurkchiev S. Evaluation of IL-1A expression in endometriotic lesions using quantitative immunohistochemistry approach. C R Acad Bulg Sci, 2006; 2: 229
5. Jiang Z, Woda BA, Wu CL, Yang XJ. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S). Am J Clin Pathol, 2004; 122: 275-289
6. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR. P63 is the molecular switch for initiation of an epithelial stratification program. Genes Dev, 2004; 18: 126-131
7. Kuefer R, Varambally S, Zhou M, Lucas PC, Loeffler M, Wolter H, Mattfeldt T, Hautmann RE, Gschwend JE, Barrette TR, Dunn RL, Chinnaiyan AM, Rubin MA. Alpha-methylacyl-CoA racemase: expression levels of this novel cancer biomarker depend on tumor differentiation. Am J Pathol, 2002; 161: 841-848
8. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL Isaacs JT. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res, 2006; 66: 8598-8607
9. Liu AY, True LD, LaTray L, Ellis WJ, Vessella RL, Lange PH, Higano CS, Hood L, van den Engh G. Analysis and sorting of prostate cancer cell types by flow cytometry. Prostate, 1999; 40: 192-199
10. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Matzo AM. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res, 2002; 62: 2220-2226
11. Matkowskyj KA, Cox R, Jensen RT, Benya RV. Quantitative immunohistochemistry by measuring cumulative signal strength accurately measures receptor number. J Histochem Cytochem, 2003; 51: 205-214
12. Matkowskyj KA, Schonfeld D, Benya RV. Quantitative immunohistochemistry by measuring, cumulative signal strength using commercially available software photoshop and matlab. J Histochem Cytochem, 2000; 48: 303-312
13. McKeon F. P63 and the epithelial stem cell: more than status quo? Genes Dev, 2004; 18: 465-469
14. Nagle RB, Ahmann FR, McDaniel KM, Paquin ML, Clark VA, Celniker A. Cytokeratin characterization of human prostatic carcinoma and its derived cell lines. Cancer Res, 1987; 47: 281-286
15. Nakayama M, Bennett CJ, Hicks JL, Epstein JI, Platz EA, Nelson WG, De Marzo AM. Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am J Pathol, 2003; 163: 923-933
16. Nelson WG, De Marzo AM, DeWeese TL. The molecular pathogenesis of prostate cancer: implications for prostate cancer prevention. Urology, 2001; 57, Suppl 1: 39-45
17. Parsons JK, Gage WR, Nelson WG, De Matzo AM. P63 protein expression is rare in prostate adenocarcinoma: implications for cancer diagnosis and carcinogenesis. Urology, 2001; 58: 619-624
18. Rizzo S, Attard G, Hudson DL. Prostate epithelial stem cells. Cell Prolif, 2005; 38: 363-374
19. Rubin MA, Bismar TA, Andren O, Mucci L, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami HO, Kantoff PW, Johansson JE. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev, 2005; 14: 1424-1432
20. Schalken JA, van Leenders G. Cellular and molecular biology of the prostate: stem cell biology. Urology, 2003; 62, Suppl 1: 11-20
21. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. P63 is a prostate basal cell marker and is required for prostate development. Am J Pathol, 2000; 157: 1769-1775
22. Tokar EJ, Ancrile BB, Cunha GR, Webber MM. Stem/progenitor and intermediate cell types and the origin of human prostate cancer. Differentiation, 2005; 73: 463-473
23. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res, 2002; 1: 113-121
24. van Leenders GJ, Gage WR, Hicks JL, van Balken B, Aalders TW, Schalken JA, De Marzo AM. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol, 2003; 162: 1529-1537
25. van Leenders GJ, Schalken JA. Stem cell differentiation within the human prostate epithelium: implications for prostate carcinogenesis. BJU Int, 2001; 88, Suppl 2: 35-42
26. Verhagen AP, Ramaekers FC, Aalders TW, Schaafsma HE, Debruyne FM, Schalken JA. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res, 1992; 52: 6182-6187
27. Westfall MD, Pietenpol JA. P63: molecular complexity in development and cancer. Carcinogenesis, 2004; 25: 857-864
28. Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT, Tabin C, Sharpe A, Caput D, Cram C, McKeon F. P63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature, 1999; 398: 714-718